Cytokinetics INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ

26 Feb 2026

CYTK

10-K: Cytokinetics Secures Global Approvals for MYQORZO, Expands Pipeline

Cytokinetics reports FDA, EU, and China approvals for MYQORZO (aficamten) for oHCM, while advancing its cardiology and neuromuscular pipeline and facing significant financial losses.

NASDAQ

27 Feb 2025

CYTK

Cytokinetics INC

10-K: Cytokinetics' 2024 10-K Filing: Aficamten NDA Accepted, Omecamtiv Mecarbil Trial Progresses

Cytokinetics' 2024 10-K filing highlights the acceptance of the aficamten NDA, progress in the omecamtiv mecarbil COMET-HF trial, and strategic collaborations to advance its muscle biology-focused pipeline.

NASDAQ

28 Feb 2024

CYTK

Cytokinetics INC

10-K: Cytokinetics Reports Full Year 2023 Results, Provides Update on Key Programs

Cytokinetics' 10-K filing reveals a year of significant R&D investment and strategic positioning for potential commercial launches, alongside ongoing regulatory challenges.